Sep. 24 at 4:58 AM
$RNXT RenovoRx
RenovoRx Inc.
(RNXT)
is a California-based biotech company that offers targeted oncology therapies, which saw a spurt in Momentum over the past week, with its Edge scores soaring 56.86 points, from 23.34 to 80.2.
This can be attributed to its recent second-quarter revenues, which beat estimates, alongside the robust uptake of its RenovoCath device, which expanded from five cancer centers to 13 during the quarter.
HC Wainwright analyst Swayampakula Ramakanth maintained a “Buy” rating and
$3 price target, citing accelerating sales and a growing commercialization strategy, representing an upside of 141%.
